Targets › Tubulin
72 programs from 54 companies in 478 trials: 247 Phase 2, 120 Phase 1, 80 Phase 3, 31 Phase 4; Oncology, Genitourinary, Other; next expected readout Nov 2026.
Open in Phaseline: the race on Tubulin, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Brigham and Women's Hospital | MIB 626 (NMN) Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2C | Phase 4 | Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension … | Nov 2026 |
| M.D. Anderson Cancer Center | [18F]-4FN PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2, CHRNB2, CHRNA4, Tubulin, OPRM1, CD274 | Phase 4 | Lymphoma; Tobacco Use Cessation; Cigarette Smoking-Related Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm … | Dec 2026 |
| Astellas | Enfortumab Vedotin Nectin-4 binding agent; Tubulin inhibitor | NECTIN4, Tubulin | Phase 4 | Metastatic Urothelial Carcinoma; Urothelial Cancer; Locally Advanced or Metastatic Malignant Solid Tumors; Muscle-invasive Bladder Cancer … | Dec 2026 |
| Urotronic | Optilume Urethral DCB Paclitaxel-coated balloon catheter | Tubulin | Phase 4 | Urethral Stricture | Jun 2027 |
| Takeda | Brentuximab Vedotin Tubulin inhibitor; Tumor necrosis factor receptor superfamily member 8 binding agent | Tubulin, TNFRSF8 | Phase 4 | Hodgkin Lymphoma; Lymphoma; Hodgkin Disease; Ann Arbor Stage III Hodgkin Lymphoma … | Dec 2027 |
| Pfizer | Tisotumab Vedotin Tubulin inhibitor; Coagulation factor III binding agent | Tubulin, F3 | Phase 4 | Cervical Cancer | Dec 2028 |
| Vastra Gotaland Region | Optilume Paclitaxel-coated dilatation balloon | Tubulin | Phase 4 | Urethral Stricture | Feb 2029 |
| AbbVie | Mirvetuximab Soravtansine Folate receptor alpha binding agent; Tubulin inhibitor | FOLR1, Tubulin | Phase 3 | Ovarian Cancer; High Grade Ovarian Cancer; Recurrent Ovarian Cancer; Advanced High-Grade Epithelial Ovarian Cancer … | Nov 2026 |
| Sichuan Kelun-Biotech Biopharmaceutical | Trastuzumab Botidotin (A166) Receptor tyrosine-protein kinase erbB-2 binding agent; Tubulin inhibitor | ERBB2, Tubulin | Phase 3 | HER2-positive Breast Cancer; Her 2 Positive Breast Cancer | Nov 2026 |
| RemeGen | Disitamab Vedotin Receptor tyrosine-protein kinase erbB-2 binding agent; Tubulin disrupting agent | ERBB2, Tubulin | Phase 3 | Urothelial Carcinoma; Breast Cancer; Gastric Carcinoma; Gastric Cancer … | Dec 2026 |
| National Cancer Institute (NCI) | Vinblastine Tubulin inhibitor | Tubulin | Phase 3 | Recurrent Low Grade Astrocytoma | Dec 2026 |
| GSK | Belantamab mafodotin Tumor necrosis factor receptor superfamily member 17 binding agent; Tubulin inhibitor | TNFRSF17, Tubulin | Phase 3 | Multiple Myeloma; Amyloidosis; Plasma Cell Myeloma; Myeloma Multiple … | Dec 2026 |
| Sun Yat-sen University | TPF induction chemotherapy Combination chemotherapy: polymeric micellar paclitaxel (taxane microtubule inhibitor), ci | Tubulin, TP53 | Phase 3 | Nasopharyngeal Carcinoma | Dec 2026 |
| State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia | Vinblastine Tubulin inhibitor | Tubulin | Phase 3 | Hodgkin Lymphoma, Adult | Dec 2026 |
| Roche | Polatuzumab vedotin B-cell antigen receptor complex-associated protein beta chain binding agent; Tubulin inhibitor | CD79B, Tubulin | Phase 3 | Non-Hodgkin Lymphoma; Large B-Cell Lymphoma; B-cell Non-Hodgkin Lymphoma; Non-Hodgkins Lymphoma … | Feb 2027 |
| Zero Point Five Therapeutics | ZP5-9676 Broad-spectrum benzimidazole anthelmintic | Tubulin | Phase 3 | Soil-Transmitted Helminthiasis (STH) | Mar 2027 |
| Roche | Trastuzumab Emtansine Receptor protein-tyrosine kinase erbB-2 binding agent; Tubulin inhibitor | ERBB2, Tubulin | Phase 3 | Breast Cancer; Ovarian Cancer; Metastatic Solid Tumor; Early Breast Cancer … | Mar 2027 |
| Merck & Co. (MSD) | EV (Enfortumab Vedotin) Nectin-4 binding agent; Tubulin inhibitor | NECTIN4, Tubulin | Phase 3 | Urinary Bladder Cancer, Muscle-invasive; Bladder Cancer; Metastatic Urothelial Carcinoma | May 2027 |
| National Cancer Institute (NCI) | Eribulin Mesylate Tubulin inhibitor | Tubulin | Phase 3 | Metastatic Bladder Urothelial Carcinoma; Locally Advanced Bladder Urothelial Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Advanced Urothelial Carcinoma | May 2027 |
| Sun Yat-sen University | Utidelone Microtubule-stabilizing agent; taxane-class chemotherapy | Tubulin | Phase 3 | Breast Neoplasms | Jun 2027 |
| Sichuan Kelun-Biotech Biopharmaceutical | Eribulin (SKB264) Tubulin inhibitor | Tubulin | Phase 3 | Triple Negative Breast Cancer | Jun 2027 |
| First Affiliated Hospital, Sun Yat-Sen University | Induction Chemotherapy (TPF regimen) Docetaxel, cisplatin, and 5-fluorouracil combination | Tubulin, TP53, TYMS, RRM1 | Phase 3 | Locally Advanced Nasopharyngeal Carcinoma | Aug 2027 |
| GIE Medical | GIE Medical ProTractX3 TTS DCB Paclitaxel-coated balloon catheter | Tubulin | Phase 3 | Bowel; Stricture; Esophageal Stricture | Dec 2027 |
| National Institute of Cardiovascular Diseases, Pakistan | paclitaxel-coated drug coated balloon (Prevail DCB, Medtronic Inc.) paclitaxel-coated balloon catheter; paclitaxel is a microtubule stabilizer that inhibits c | Tubulin | Phase 3 | STEMI (ST Elevation MI) | Dec 2027 |
| AbbVie | Telisotuzumab Vedotin (ABBV-399) Tubulin inhibitor; Hepatocyte growth factor receptor binding agent | Tubulin, MET | Phase 3 | Non Small Cell Lung Cancer; Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer; Advanced Solid Tumors Cancer … | Feb 2028 |
| Fidia Farmaceutici | ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID) Paclitaxel (microtubule stabilizer) formulated with hyaluronic acid for intravesical deliv | Tubulin | Phase 3 | Bladder Carcinoma in Situ (CIS) | May 2028 |
| UNICANCER | Cabazitaxel Tubulin inhibitor | Tubulin | Phase 3 | Adenocarcinoma of Prostate | Jul 2041 |
| European Organisation for Research and Treatment of Cancer - EORTC | ABVD regimen Combination of doxorubicin, bleomycin, vinblastine, and dacarbazine - multi-modal chemothe | Tubulin, TOP2A, MYC | Phase 3 | Lymphoma | – |
| European Organisation for Research and Treatment of Cancer - EORTC | BEACOPP regimen Combination of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbaz | TOP2A, Tubulin | Phase 3 | Lymphoma | – |
| European Organisation for Research and Treatment of Cancer - EORTC | Vinblastine Tubulin inhibitor | Tubulin | Phase 3 | Lymphoma | – |
| European Organisation for Research and Treatment of Cancer - EORTC | vincristine sulfate Tubulin inhibitor | Tubulin | Phase 3 | Lymphoma | – |
| Memorial Sloan Kettering Cancer Center | Plinabulin Tubulin inhibitor | Tubulin | Phase 2 | Multiple Myeloma | Nov 2026 |
| Ambrx | Anvatabart Opadotin (ARX788) Tubulin inhibitor; Receptor protein-tyrosine kinase erbB-2 binding agent | Tubulin, ERBB2 | Phase 2 | HER2 Positive Metastatic Breast Cancer; Breast Neoplasms; HER2-positive, Metastatic Breast Cancer; HER2-positive Breast Cancer … | Dec 2026 |
| Shanghai Jiao Tong University School of Medicine | Cabazitaxel Tubulin inhibitor | Tubulin | Phase 2 | Prostate Cancer Patients | Dec 2026 |
| Fudan University | Albumin-paclitaxel Microtubule stabilizer, promotes tubulin polymerization | Tubulin | Phase 2 | Paget Disease, Extramammary | Dec 2026 |
| Institut du Cancer de Montpellier - Val d'Aurelle | Gembrax Gemcitabine and albumin-bound paclitaxel combination | Tubulin | Phase 2 | Metastatic Pancreatic Cancer | Dec 2026 |
| Henan Cancer Hospital | Utidelone Microtubule-stabilizing agent; tubulin polymerization inhibitor | Tubulin | Phase 2 | HER-2 Negative Breast Cancer; Metastatic Breast Cancer | Dec 2026 |
| Min Yan, MD | Utidelone Capsule Microtubule destabilizer; tubulin-binding agent | Tubulin | Phase 2 | Breast Cancer Recurrent | Dec 2026 |
| M.D. Anderson Cancer Center | Ixabepilone Tubulin inhibitor | Tubulin | Phase 2 | Bilateral Breast Carcinoma | Dec 2026 |
| Peking Union Medical College Hospital | Plinabulin Tubulin inhibitor | Tubulin | Phase 2 | Non Small Cell Lung Cancer Metastatic | Dec 2026 |
| Beijing Biostar Pharmaceuticals | Utidelone Capsule (UTD2) Microtubule stabilizer; tubulin inhibitor | Tubulin | Phase 2 | Gastric or Gastroesophageal Junction Adenocarcinoma; Advanced Solid Tumor | Dec 2026 |
| National Cancer Institute (NCI) | Anetumab Ravtansine Mesothelin binding agent; Tubulin inhibitor | MSLN, Tubulin | Phase 2 | Fallopian Tube Endometrioid Adenocarcinoma; Pancreatic Adenocarcinoma; Pleural Malignant Mesothelioma | Jan 2027 |
| National Cancer Institute (NCI) | Ixabepilone Tubulin inhibitor | Tubulin | Phase 2 | Endometrial Adenocarcinoma; Adult Solid Neoplasm | Mar 2027 |
| Asan Medical Center | Liporaxel Microtubule stabilizer (paclitaxel formulation) | Tubulin | Phase 2 | Gastrointestinal Stromal Tumors | Mar 2027 |
| Pfizer | tisotumab vedotin Tubulin inhibitor; Coagulation factor III binding agent | Tubulin, F3 | Phase 2 | Colorectal Neoplasms | Mar 2027 |
| Erasmus Medical Center | Cabazitaxel Tubulin inhibitor | Tubulin | Phase 2 | Metastatic Castration-resistant Prostate Cancer | May 2027 |
| Criterium | Eribulin Tubulin inhibitor | Tubulin | Phase 2 | Breast Cancer | Jun 2027 |
| Roche | Trastuzumab Emtansine Receptor protein-tyrosine kinase erbB-2 binding agent; Tubulin inhibitor | ERBB2, Tubulin | Phase 2 | Neoplasm Metastasis | Jun 2027 |
| M.D. Anderson Cancer Center | Cabazitaxel Tubulin inhibitor | Tubulin | Phase 2 | Aggressive Variant Prostate Carcinoma; Castration Levels of Testosterone | Dec 2027 |
| Case Comprehensive Cancer Center | Cabazitaxel Tubulin inhibitor | Tubulin | Phase 2 | Metastatic Prostate Cancer | Feb 2028 |
| ECOG-ACRIN Cancer Research Group | Cabazitaxel Tubulin inhibitor | Tubulin | Phase 2 | Castration Levels of Testosterone | Apr 2028 |
| Andrew J. Armstrong, MD | Cabazitaxel Tubulin inhibitor | Tubulin | Phase 2 | Metastatic Prostate Neuroendocrine Carcinoma | Aug 2028 |
| The First Affiliated Hospital of Soochow University | Vindesine Vinca alkaloid; microtubule inhibitor | Tubulin | Phase 2 | Adult T-cell Leukemia/Lymphoma | Sep 2028 |
| St. Jude Children's Research Hospital | Vinblastine Tubulin inhibitor | Tubulin | Phase 2 | Hodgkin Lymphoma | Oct 2028 |
| St. Jude Children's Research Hospital | Vincristine Sulfate Tubulin inhibitor | Tubulin | Phase 2 | Brain and Central Nervous System Tumors | Apr 2029 |
| New York Medical College | Vinblastine Tubulin inhibitor | Tubulin | Phase 2 | Anaplastic Large Cell Lymphoma, ALK-Positive | Jul 2029 |
| St. Petersburg State Pavlov Medical University | Vinblastine Tubulin inhibitor | Tubulin | Phase 2 | Hodgkin Lymphoma | Oct 2029 |
| Shanton Pharma Pte. | Colchicine (SAP-001) Tubulin inhibitor | Tubulin | Phase 2 | Gout; Colchicine; Persistent Atrial Fibrillation; Coronary Artery Disease … | – |
| Xiaorong Dong | Plinabulin Tubulin inhibitor | Tubulin | Phase 2 | Small Cell Lung Cancer Extensive Stage | – |
| North American Consortium for Histiocytosis | Vinblastine Tubulin inhibitor | Tubulin | Phase 2 | Langerhans Cell Histiocytosis | – |
| Peter MacCallum Cancer Centre, Australia | Cabazitaxel Tubulin inhibitor | Tubulin | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Dec 2026 |
| PanTher Therapeutics | PTM-101 paclitaxel-based absorbable drug product; microtubule stabilizer | Tubulin | Phase 1 | Pancreatic Ductal Adenocarcinoma | Dec 2026 |
| OHSU Knight Cancer Institute | Cabazitaxel Tubulin inhibitor | Tubulin | Phase 1 | Castration-Resistant Prostate Carcinoma | Jan 2027 |
| Takeda | Mirvetuximab Soravtansine (TAK-853) Folate receptor alpha binding agent; Tubulin inhibitor | FOLR1, Tubulin | Phase 1 | Ovarian Cancer | Mar 2027 |
| Eisai | Eribulin (E7389) Tubulin inhibitor | Tubulin | Phase 1 | Solid Tumor; Solid Neoplasms; Breast Neoplasms; Breast Cancer Stage IV … | Mar 2027 |
| Jiangsu Simcere Pharmaceutical | SIM0388 Docetaxel polymeric micelle formulation (microtubule stabilizer) | Tubulin | Phase 1 | Malignant Ascites | Jun 2027 |
| University of California, San Diego | nL-TUBB4-001 Antisense oligonucleotide targeting TUBB4A | Tubulin | Phase 1 | Genetic Disease | Sep 2027 |
| PharmaMatrix Holdings Ltd | CCI-001 Colchicine derivative; β-III tubulin binder | Tubulin | Phase 1 | Cancer: Recurrent and/or Metastatic Solid Tumours | Dec 2027 |
| Guarionex J. Decastro | Cabazitaxel Tubulin inhibitor | Tubulin | Phase 1 | Urothelial Carcinoma of the Urinary Bladder | Apr 2028 |
| ECOG-ACRIN Cancer Research Group | Vincristine Sulfate Tubulin inhibitor | Tubulin | Phase 1 | Recurrent Adult Lymphoblastic Lymphoma | Dec 2028 |
| St. Justine's Hospital | Vinblastine Tubulin inhibitor | Tubulin | Phase 1 | Pediatric Low-grade Glioma | Apr 2030 |
| Roche | Ladiratuzumab Vedotin Tubulin inhibitor; Zinc transporter ZIP6 binding agent | Tubulin, SLC39A6 | Phase 1 | Metastatic Breast Cancer | Sep 2030 |
Multiple Myeloma (27) Breast Cancer (12) Hodgkin Lymphoma (10) Bladder Cancer (9) Lymphoma (9) Diffuse Large B-Cell Lymphoma (8) Urothelial Carcinoma (6) Gastric Cancer (6) Ovarian Cancer (6) Acute Myeloid Leukemia (6) Solid Tumor (5) Prostate Cancer (5)
small molecule (36), mixed (18), antibody (9), protein or peptide (2)
Roche (4) National Cancer Institute (NCI) (4) European Organisation for Research and Treatment of Cancer - EORTC (4) M.D. Anderson Cancer Center (3) Takeda (2) Sichuan Kelun-Biotech Biopharmaceutical (2) Pfizer (2) St. Jude Children's Research Hospital (2) ECOG-ACRIN Cancer Research Group (2) Sun Yat-sen University (2) AbbVie (2) RemeGen (1) Henan Cancer Hospital (1) Fidia Farmaceutici (1) GSK (1) Beijing Biostar Pharmaceuticals (1) Min Yan, MD (1) Urotronic (1) Guarionex J. Decastro (1) Erasmus Medical Center (1)
ERBB2 (5) F3 (2) TOP2A (2) TP53 (2) NECTIN4 (2) OPRM1 (2) FOLR1 (2) TNFRSF8 (1) TNFRSF17 (1) MYC (1) TYMS (1) RRM1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.